Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR tyrosine kinase inhibitor treatment.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

World Journal of Clinical Cases Pub Date : 2024-11-16 DOI:10.12998/wjcc.v12.i32.6543

Ruo-Bing Qi, Zheng-Hao Wu

引用次数: 0

Abstract

In this editorial we comment on the article by Ji et al. We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.

查看原文本刊更多论文

表皮生长因子受体酪氨酸激酶抑制剂治疗后，表皮生长因子受体19-del突变的晚期肺腺癌转变为鳞癌。

在这篇社论中，我们对 Ji 等人的文章进行了评论。我们特别关注表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的治疗以及 EGFR-TKIs 耐药性的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Clinical Cases Medicine-General Medicine

自引率

0.00%

发文量

3384

期刊介绍： The World Journal of Clinical Cases (WJCC) is a high-quality, peer reviewed, open-access journal. The primary task of WJCC is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of clinical cases. In order to promote productive academic communication, the peer review process for the WJCC is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCC are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in clinical cases.